Late sodium current inhibition as a new cardioprotective approach (Q37156945)

18 August 2017

1 reference

title

Late sodium current inhibition as a new cardioprotective approach (English)

1 reference

18 August 2017

0 references

Sharon L Hale

1

1 reference

18 August 2017

John C Shryock

2

1 reference

18 August 2017

Luiz Belardinelli

3

1 reference

18 August 2017

Michael Sweeney

4

1 reference

18 August 2017

Robert A Kloner

5

1 reference

18 August 2017

8 April 2008

1 reference

Journal of Molecular and Cellular Cardiology

18 August 2017

1 reference

18 August 2017

44

1 reference

18 August 2017

6

1 reference

18 August 2017

954-967

1 reference

Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Na+ channels as targets for neuroprotective drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Cardioprotective actions of KC 12291. II. Delaying Na+ overload in ischemia improves cardiac function and energy status in reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Drugs preventing Na+ and Ca2+ overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

The role of the persistent Na(+) current during cardiac ischemia and hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ionic basis of ischaemic cardiac injury: insights from cellular studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Deleterious effects of digitalis on reperfusion-induced arrhythmias and myocardial injury in ischemic rat hearts: possible involvements of myocardial Na+ and Ca2+ imbalance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Cardioprotective actions of KC 12291. I. Inhibition of voltage-gated Na+ channels in ischemia delays myocardial Na+ overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Intracellular Na+ regulation in cardiac myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Contribution of the Na(+) channel and Na(+)/H(+) exchanger to the anoxic rise of [Na(+)] in ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Calcium-induced release of calcium from the sarcoplasmic reticulum of skinned cells from adult human, dog, cat, rabbit, rat, and frog hearts and from fetal and new-born rat ventricles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Calcium overload and cardiac function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Cardiac-specific ablation of the Na+-Ca2+ exchanger confers protection against ischemia/reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Hydroxyl radical-induced acute diastolic dysfunction is due to calcium overload via reverse-mode Na(+)-Ca(2+) exchange

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

The role of the Na+ channel in the accumulation of intracellular Na+ during myocardial ischemia: consequences for post-ischemic recovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Role of Na(+)/H(+) exchanger during ischemia and preconditioning in the isolated rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Dependence of hypoxic cellular calcium loading on Na(+)-Ca2+ exchange

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Hypoxia increases persistent sodium current in rat ventricular myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Vitamin C pretreatment attenuates hypoxia-induced disturbance of sodium currents in guinea pig ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Induction of persistent sodium current by exogenous and endogenous nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Slow inactivation of a tetrodotoxin-sensitive current in canine cardiac Purkinje fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Mechanism of inactivation of single sodium channels after modification by chloramine-T, sea anemone toxin and scorpion toxin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

On the molecular nature of the lidocaine receptor of cardiac Na+ channels. Modification of block by alterations in the alpha-subunit III-IV interdomain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Na channels that remain open throughout the cardiac action potential plateau.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Na(+) current in human ventricle: implications for sodium loading and homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Inactivation-resistant channels underlying the persistent sodium current in rat ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Resurgent sodium current and action potential formation in dissociated cerebellar Purkinje neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Tetrodotoxin differentially blocks peak and steady-state sodium channel currents in early embryonic chick ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Pharmacological targeting of long QT mutant sodium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Late sodium current is a novel target for amiodarone: studies in failing human myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

A phosphorylation site in the Na+ channel required for modulation by protein kinase C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Modulation of Cardiac Sodium Channel Gating by Protein Kinase A Can Be Altered by Disease-linked Mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Oxygen-sensing persistent sodium channels in rat hippocampus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Acute and chronic hypoxic regulation of recombinant hNa(v)1.5 alpha subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

The effects of the Anemonia sulcata toxin (ATX II) on membrane currents of isolated mammalian myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Persistent sodium current in mammalian central neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Inhibition of oxidative metabolism increases persistent sodium current in rat CA1 hippocampal neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Molecular basis of an inherited epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

The roles of sodium channels in nociception: Implications for mechanisms of pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Different pathways for sodium entry in cardiac cells during ischemia and early reperfusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Blocking Na(+)-H+ exchange by cariporide reduces Na(+)-overload in ischemia and is cardioprotective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Protective Effects of Ranolazine on Ventricular Fibrillation Induced by Activation of the ATP-Dependent Potassium Channel in the Rabbit Heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Optimal medical therapy with or without PCI for stable coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2008.03.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YJMCC.2008.03.019

1 reference

18 August 2017

1 reference